Seres Therapeutics Inc (NASDAQ:MCRB) has been given a consensus recommendation of “Buy” by the twelve analysts that are presently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a sell recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $19.14.

Several equities research analysts have issued reports on the stock. Zacks Investment Research lowered shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. BidaskClub lowered shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, February 7th.

Several institutional investors and hedge funds have recently bought and sold shares of MCRB. Schwab Charles Investment Management Inc. grew its holdings in shares of Seres Therapeutics by 0.5% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 91,543 shares of the biotechnology company’s stock worth $1,035,000 after purchasing an additional 494 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Seres Therapeutics by 14.8% in the 2nd quarter. Rhumbline Advisers now owns 22,472 shares of the biotechnology company’s stock worth $254,000 after purchasing an additional 2,890 shares during the last quarter. Swiss National Bank grew its holdings in shares of Seres Therapeutics by 41.8% in the 2nd quarter. Swiss National Bank now owns 33,600 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 9,900 shares during the last quarter. Alliancebernstein L.P. grew its holdings in shares of Seres Therapeutics by 27.6% in the 2nd quarter. Alliancebernstein L.P. now owns 41,600 shares of the biotechnology company’s stock worth $470,000 after purchasing an additional 9,000 shares during the last quarter. Finally, Teachers Advisors LLC grew its holdings in shares of Seres Therapeutics by 1.2% in the 2nd quarter. Teachers Advisors LLC now owns 38,758 shares of the biotechnology company’s stock worth $438,000 after purchasing an additional 450 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Shares of Seres Therapeutics (MCRB) traded up $0.24 during trading on Friday, reaching $8.87. 89,953 shares of the company’s stock traded hands, compared to its average volume of 147,224. The company has a market cap of $351.80, a price-to-earnings ratio of -4.18 and a beta of 0.24. The company has a debt-to-equity ratio of 0.11, a current ratio of 6.53 and a quick ratio of 6.53. Seres Therapeutics has a 12-month low of $7.90 and a 12-month high of $17.42.

TRADEMARK VIOLATION WARNING: “Seres Therapeutics Inc (MCRB) Receives Average Recommendation of “Buy” from Brokerages” was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://theolympiareport.com/2018/02/15/seres-therapeutics-inc-mcrb-receives-average-recommendation-of-buy-from-brokerages.html.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.